Marchevsky et al. [34] predicted the survival of Stage I and II NSCLC patients using clinical-pathological (age, sex, cell type, stage, tumour grade, smoking history) and immunohistochemical variables (c-erbB-3, bcl-2, Glut1, Glut3, retinoblastoma gene and p53). The gene discussed is TP53; the disease is non-small cell lung carcinoma.